ConductScience.org, home

Paper37489367

Development of a Novel Anti-CD44 Variant 8 Monoclonal Antibody C44Mab-94 against Gastric Carcinomas.

Suzuki H and 5 others. Antibodies (Basel), 2023. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. Development of a Novel Anti-CD44 Variant 8 Monoclonal Antibody C44Mab-94 against Gastric Carcinomas. Papers, record 37489367. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37489367

Download JSON
Cell line
CHO/CD44v3-108 papers
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Development of a Novel Anti-CD44 Variant 8 Monoclonal Antibody C44Mab-94 against Gastric Carcinomas.
PubMed
Journal
Antibodies (Basel)
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
3
iCite
Relative citation ratio, by iCite
0.43
iCite
Revised in PubMed
2023-07-27
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Suzuki HHiroyukihttps://orcid.org/0000-0003-2646-5132
2Goto NNohara
3Tanaka TTomohiro
4Ouchida TTsunenori
5Kaneko MKMika K
6Kato YYukinarihttps://orcid.org/0000-0001-5385-8201

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
JP22ama121008 (to Y.K.), JP22am0401013 (to Y.K.), JP22bm1004001 (to Y.K.), JP22ck0106730 (to Y.K.), and JP21am0101078 (to Y.K.)Japan Agency for Medical Research and DevelopmentPubMed
21K20789 (to T.T.), 22K06995 (to H.S.), 21K07168 (to M.K.K.), and 22K07224 (to Y.K.)Japan Society for the Promotion of SciencePubMed

Source PubMed

Download CSV of grants

References61

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
134424761Development of a Novel Epitope Mapping System: RIEDL Insertion for Epitope Mapping Method.Monoclon Antib Immunodiagn Immunother2021https://conductscience.org/library/papers/34424761PubMed
27532175Proteoglycan forms of the lymphocyte homing receptor CD44 are alternatively spliced variants containing the v3 exon.J Cell Biol1995https://conductscience.org/library/papers/7532175PubMed
39003471Characterization of a high-affinity monoclonal antibody specific for CD44v6 as candidate for immunotherapy of squamous cell carcinomas.Cancer Immunol Immunother1996https://conductscience.org/library/papers/9003471PubMed
425894828Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes.Nat Med2015https://conductscience.org/library/papers/25894828PubMed
511992408Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head-and-neck cancer xenografts.Int J Cancer2002https://conductscience.org/library/papers/11992408PubMed
636660940Antitumor activities of a defucosylated anti‑EpCAM monoclonal antibody in colorectal carcinoma xenograft models.Int J Mol Med2023https://conductscience.org/library/papers/36660940PubMed
735121863Multi-omic profiling of peritoneal metastases in gastric cancer identifies molecular subtypes and therapeutic vulnerabilities.Nat Cancer2021https://conductscience.org/library/papers/35121863PubMed
835628345Development of a Novel Anti-CD44 Monoclonal Antibody for Multiple Applications against Esophageal Squamous Cell Carcinomas.Int J Mol Sci2022https://conductscience.org/library/papers/35628345PubMed
932117253CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice.Front Immunol2020https://conductscience.org/library/papers/32117253PubMed
1035991754Efficacy of cancer-specific anti-podoplanin CAR-T cells and oncolytic herpes virus G47Δ combination therapy against glioblastoma.Mol Ther Oncolytics2022https://conductscience.org/library/papers/35991754PubMed
1137185762A Novel Anti-CD44 Variant 9 Monoclonal Antibody C44Mab-1 Was Developed for Immunohistochemical Analyses against Colorectal Cancers.Curr Issues Mol Biol2023https://conductscience.org/library/papers/37185762PubMed
1217062682A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus.Clin Cancer Res2006https://conductscience.org/library/papers/17062682PubMed
1333000243A defucosylated anti‑CD44 monoclonal antibody 5‑mG2a‑f exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma.Oncol Rep2020https://conductscience.org/library/papers/33000243PubMed
1414320675THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION.Acta Pathol Microbiol Scand1965https://conductscience.org/library/papers/14320675PubMed
1535363934CD44v3,8-10 is essential for Slug-dependent vimentin gene expression to acquire TGF-β1-induced tumor cell motility.Cancer Sci2022https://conductscience.org/library/papers/35363934PubMed
161707342A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells.Cell1991https://conductscience.org/library/papers/1707342PubMed
178652273Splice variants of the cell surface glycoprotein CD44 associated with metastatic tumour cells are expressed in normal tissues of humans and cynomolgus monkeys.Eur J Cancer1995https://conductscience.org/library/papers/8652273PubMed
1833538338Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.CA Cancer J Clin2021https://conductscience.org/library/papers/33538338PubMed
1934944493CD44: A Multifunctional Mediator of Cancer Progression.Biomolecules2021https://conductscience.org/library/papers/34944493PubMed
2029747682The biology and role of CD44 in cancer progression: therapeutic implications.J Hematol Oncol2018https://conductscience.org/library/papers/29747682PubMed

See all 61 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn PapersSource
42955118The status quo and evolution of glycoconjugates for cancer immunotherapy.Glycoconj J2026https://conductscience.org/library/papers/42955118PubMed
38571347
Exploring the Potentials of Hyaluronic Acid-coated Polymeric Nanoparticles in Enhanced Cancer Treatment by Precision Drug Delivery, Tackling Drug Resistance, and Reshaping the Tumour Micro Environment.
Curr Med Chem2025https://conductscience.org/library/papers/38571347PubMed

Download CSV of cited by

Genes11

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/37489367

GET https://conductscience.org/api/papers/v1/37489367/references?page=2